Table 1

Baseline characteristics and sleep respiratory parameters measured at placebo

Overall mean (SD)Mild group mean (SD)Severe group mean (SD)
n 604515
Age, years44.4 (11.7)42.8 (11.3)49.2 (12.0)
BMI, kg/m2 29.3 (3.9)28.5 (3.5)32.0 (4.1)
Epworth Sleepiness Scale (ESS), n/248.3 (4.3)8.0 (4.4)9.2 (4.1)
Neck circumference, cm41.2 (3.4)40.2 (3.0)43.9 (3.3)
Systolic blood pressure, mmHg125.8 (11.1)124.9 (11.6)128.6 (9.4)
Diastolic blood pressure, mmHg81.6 (8.6)80.9 (9.0)83.7 (7.5)
T90, min4.0 (9.6)1.0 (2.6)13.3 (15.6)
T95, min92.1 (89.0)78.7 (89.0)132.2 (78.4)
SpO2 nadir, %87.2 (5.7)88.6 (4.9)83.2 (6.1)
AHI, events/hour19.1 (17.7)10.5 (4.9)44.9 (17.2)
AHI (REM), events/hour20.3 (23.4)11.8 (10.5)45.6 (32.2)
AHI (NREM), events/hour18.9 (17.7)10.3 (5.7)44.7 (16.6)
ODI, events/hour14.3 (16.0)7.0 (5.0)36.0 (18.2)
ArI, events/hour25.5 (13.9)20.3 (7.1)41 (17.7)
Medications n (%) n (%) n (%)
Antidepressant (SSRI) 7 (12)5 (11)2 (13)
Antihypertensive 5 (8)3 (7)2 (13)
Antihypercholesterolaemic 6 (10)4 (9)2 (13)
  • Biometrics measured at the screening visit. Polysomnography variables measured during the placebo night. Medications subjectively reported via questionnaire during screening visit. Mild group: AHI at placebo visit < 20  events/hour; severe group: AHI at placebo visit ≥ 20  events/hour.

  • AHI, apnoea–hypopnoea index; Arl, arousal index; BMI, body mass index; N1, stage N1 sleep; N2, stage N2 sleep; NREM, non-rapid eye movement sleep; ODI, oxygen desaturation index; REM, rapid eye movement sleep; SE, sleep efficiency; SOL, sleep onset latency; SpO2nadir, oxygen saturation nadir; SWS, slow wave sleep; TST, total sleep time; WASO, wake after sleep onset.